molecules-logo

Journal Browser

Journal Browser

Extraction, Isolation, and Identification of Bioactive Compounds from Plants

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 1066

Special Issue Editors


E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Laurentian University, School of Natural Sciences, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada
Interests: Brassicales; Malpighiales; glucosinolates; isothiocyanates; phytoalexins; flavonoids; antioxidants; antifungals; biosynthesis; biotransformations

Special Issue Information

Dear Colleagues,

Plants are sources of bioactive natural compounds. Due to the variety of their chemical nature and diverse properties, these substances can be potentially exploited for several applications in different sectors such as agriculture, food, cosmetic, and health industries. The knowledge about the vast natural compound domain is continuously evolving and attracting a community of scientists of several disciplines involved in multidisciplinary research projects.

This Special Issue welcomes research articles and reviews that highlight recent advances in the study of natural compounds, including: their screening in different wild and cultivated plant species, methods for their extraction, isolation, and identification (characterization by mass spectrometry and NMR), in addition to studying their in vitro and in vivo bioactivity; the elucidation of their mechanism of action; the investigation of their stability and functionality for potential practical application in different fields.

Dr. Gina Rosalinda De Nicola
Dr. Sabine Montaut
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • extraction methods
  • isolation methods
  • chromatography
  • chemical characterization
  • bioactivity
  • antioxidant
  • antimicrobial
  • antiinflammation
  • bio-guided assay
  • biopesticides
  • biostimulants
  • nutraceuticals

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1735 KiB  
Article
Selective Activity of Chrysin-6-C-Fucopyranoside from Cyclanthera pedata Toward Peroxisome Proliferator-Activated Receptor Gamma
by Marco Zuccolo, Angela Bassoli, Gigliola Borgonovo, Luca Giupponi, Annamaria Giorgi, Aniello Schiano Moriello and Fabio Arturo Iannotti
Molecules 2025, 30(7), 1626; https://doi.org/10.3390/molecules30071626 - 5 Apr 2025
Viewed by 348
Abstract
Caigua (Cyclanthera pedata (L.) Schrad.) is a traditional herbal remedy traditionally used in Latin America for its health benefits and to treat metabolic disorders, including diabetes. Despite interest in its herbal use, the phytochemical properties of caigua’s secondary metabolites are poorly known. [...] Read more.
Caigua (Cyclanthera pedata (L.) Schrad.) is a traditional herbal remedy traditionally used in Latin America for its health benefits and to treat metabolic disorders, including diabetes. Despite interest in its herbal use, the phytochemical properties of caigua’s secondary metabolites are poorly known. This study aimed to isolate the main flavone glycosides from the leaves of caigua landrace cultivated in the Camonica Valley (Italy) using flash chromatography and evaluate their potential activity toward peroxisome proliferator-activated receptors (PPARs) and transient receptor potential (TRP) ion channels through luciferase and intracellular calcium assays. We found that the caigua species-specific flavone glycoside, chrysin-6-C-fucopyranoside, showed potent and selective activity toward PPARγ, with no effects on other PPAR subtypes or TRP channels. These findings indicate that the caigua plant could offer a safer alternative to conventional PPARγ agonists, whose use as antidiabetic drugs is limited by severe side effects that currently restrict the clinical use of conventional PPAR agonists. Full article
Show Figures

Graphical abstract

Back to TopTop